VRC 100 was designed to recruit and screen HIV-infected subjects for therapeutic HIV vaccines, as well as other vaccines to be developed for use in HIV-infected individuals. The results of this screening study were used to determine if the subject met eligibility requirements for participation a vaccine study. Educational materials on vaccines were reviewed with and provided to subjects before enrollment into a vaccine study. VRC 101 was the first Phase I therapeutic study of two candidate HIV-1 vaccines developed by VRC and administered in a prime-boost regimen.
|Lynch, Rebecca M; Boritz, Eli; Coates, Emily E et al. (2015) Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med 7:319ra206|
|Rudicell, Rebecca S; Kwon, Young Do; Ko, Sung-Youl et al. (2014) Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 88:12669-82|
|Casazza, Joseph P; Bowman, Kathryn A; Adzaku, Selorm et al. (2013) Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis 207:1829-40|
|Rosenberg, Eric S; Graham, Barney S; Chan, Ellen S et al. (2010) Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One 5:e10555|